Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany
Rhea-AI Summary
Picard Medical (NYSE American: PMI) announced that CEO Patrick NJ Schnegelsberg will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the CSI Focus D-HF conference in Frankfurt, Germany.
The conference runs December 5–6, 2025, and the presentation is scheduled for Saturday, December 6, 2025, 13:00–13:45 CET in the Red Room during the Durable Mechanical Circulatory Support session. Picard is parent of SynCardia Systems, maker of the first TAH approved by both the U.S. FDA and Health Canada.
Positive
- None.
Negative
- None.
News Market Reaction – PMI
In the Dec 4 session, PMI gained 82.67%, reflecting a significant positive market reaction. Argus tracked a peak move of +98.6% during that session. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 149.0x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Clinical durability update | Positive | -8.7% | Reported record 2,900 days support with SynCardia Total Artificial Heart. |
| Dec 03 | Conference presentation | Positive | +2.0% | Announced CEO’s Emperor TAH data presentation at CSI Focus D-HF. |
| Nov 26 | Conference data update | Positive | +1.9% | Planned in vitro Emperor TAH data presentation at ISMCS 2025 meeting. |
| Nov 19 | Pre-clinical implantation | Positive | -6.7% | Completed first in vivo Emperor TAH implantations in pre-clinical models. |
| Nov 14 | Earnings and IPO update | Positive | +10.7% | Reported Q3 2025 results, IPO proceeds, and portfolio/patent milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive milestones and updates often led to gains, but there are notable instances where seemingly positive clinical news coincided with short-term declines.
This announcement fits a stream of updates highlighting Picard’s SynCardia and Emperor Total Artificial Heart platforms. Over the last month, the company reported Q3 2025 results with IPO proceeds and improved losses on Nov 14, followed by first in vivo Emperor TAH implantations on Nov 19 and in vitro data at ISMCS 2025 on Nov 26. Subsequent news featured a CSI Focus D-HF presentation on Dec 3 and a patient achieving 2,900 days of SynCardia support on Dec 9, underscoring ongoing technical progress and visibility efforts.
Key Terms
total artificial heart medical
emperor total artificial heart (tah) medical
mechanical circulatory support medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.
Details of the presentation are below:
Date: Saturday, December 6, 2025
Time: 13:00 – 13:45 CET
Session: Durable Mechanical Circulatory Support
Location: Red Room
About CSI Focus D-HF
CSI Focus D-HF (https://www.csi-congress.org/dhf) is the leading global workshop dedicated to device-based therapies for heart failure. It brings together leading interventional cardiologists, engineers, academic researchers, and industry innovators to explore the next generation of heart failure device solutions, including ventricular restoration, neuromodulation, interatrial shunts, implantable monitoring systems, and telemedicine enabled strategies. The conference attracts an international cross-section of experts focused on advancing heart failure device therapies.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
